Post Profile

EpiPen Maker Mylan To Pay $465 Million For Shifty Medicaid Billing Practices

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether misclassification of its EpiPen emergency allergy treatment resulted in underpayment of rebates to the U.S. Medicaid healthcare program. The company has come under scrutiny for raising prices on the lifesaving EpiPen sixfold in less than a decade, making the devices unaffordable for a growing number of families.
read more


Related Posts

The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine

Business & Finance : Business Insider: Money Game

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...

EpiPen Maker Mylan Will Pay $465 Million to Settle Medicaid Overcharging Case

Business & Finance : DealBook

Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.

Mylan Surges After Quickly Settling With DoJ Over EpiPen Medicaid Rebates

Business & Finance / Personal Finance : Forbes: Personal Finance

Mylan will pay $465 million to settle with the Department of Justice over its classification of EpiPen in Medicaid rebate programs.

Mylan to pay $465-million settlement over Medicaid EpiPen rebates

Business & Finance : LA Times: Business

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...

Mylan to pay $465 million over EpiPen Medicaid rebate dispute

Health : Reuters: Health

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.


Copyright © 2016 Regator, LLC